ArticleClinical pharmacology and therapeutics2026
Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pegbing® (peginterferon alfa-2b), a pegylated interferon-alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT levels and associated with significant unmet clinical needs. The drug repositioning strategy of Pegbing® from CHB to ET aims to accelerate development and reduce costs. Through the application of pharmacometrics, the existing data from CHB patients were leveraged to inform dose selection and clinical trial design for ET patients. The pharmacokinetic/pharmacodynamic (PK/PD) model of Pegbing® for PLT and white blood cell (WBC) inhibition was established using data from a phase II trial conducted in CHB patients who received Pegbing®, and validated with data from a phase III trial. The PK/PD relationship was extrapolated to ET patients by adjusting baseline PLT and WBC levels using real-world data from ET patients receiving off-label treatment with Pegbing®. According to the parameter distribution and correlation from the extrapolated PK/PD relationship, 1,000 virtual ET patients were generated to form an in silico clinical trial, revealing that baseline PLT and WBC levels were key factors for hematologic response. Pegbing® 180 μg is expected to be an appropriate dose for future development, with an overall complete hematologic response rate of 62.3%. A higher maintenance dose may be required in patients with severe ET. Moreover, this study provides a valuable reference for drug repositioning between two indications with significant differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.